Loading...
IDXX is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong financial performance in its latest quarter, the technical indicators and options data suggest a lack of immediate upward momentum. Analysts have lowered price targets, and there are no significant positive catalysts or recent influential trades to support a strong buy decision. Holding off for clearer signals or a more favorable entry point may be prudent.
The technical indicators for IDXX show bearish momentum. The MACD histogram is negative and expanding, indicating downward pressure. RSI is at 20.295, which is neutral but close to being oversold. Moving averages are converging, suggesting indecision in the market. The stock is trading below the key pivot level of 647.242, with support at 621.703 and resistance at 672.781.

Hedge funds have significantly increased their buying activity, up 764.05% over the last quarter. The company reported strong financial growth in Q4 2025, with revenue, net income, EPS, and gross margin all showing double-digit YoY increases.
Analysts have lowered price targets across the board, citing concerns about muted Q1 growth, a softer 2026 gross margin outlook, and slower inVue placements. The MACD and options data suggest bearish sentiment. There are no recent news events or influential trades to act as positive catalysts.
In Q4 2025, IDXX delivered strong financial results. Revenue increased by 14.28% YoY to $1.09 billion, net income rose by 14.82% YoY to $248.19 million, and EPS grew by 17.56% YoY to $3.08. Gross margin also improved slightly to 60.35%, up 0.92% YoY.
Analysts have recently lowered their price targets for IDXX, with Piper Sandler reducing it to $750, UBS to $730, and Barclays to $800. While some analysts maintain a Neutral rating, others like Barclays and BTIG still see long-term potential with Overweight and Buy ratings, respectively. However, the overall sentiment reflects caution due to macro headwinds and near-term growth concerns.